AVANCE and DNA Steerable Introducers

The AVANCE and DNA steerable introducers leverage technology from BioCardia's Morph family of access catheters.

The 8.5 F AVANCE™ Steerable Introducer is intended for introducing various cardiovascular catheters into the heart, including the left side of the heart through the interatrial septum. Designed to be virtually whipless around curves, due to its helically arranged pull-wires, the AVANCE™ bi-directional introducer provides exceptional torsional stiffness to enable greater predictability, stability and control during procedures.




05145 (MKT)

The recently FDA approved DNA steerable introducer is intended to provide a pathway through which medical instruments such as balloon dilatation catheters, guidewires, or other therapeutic devices may be introduced into the peripheral vasculature or chambers and coronary vasculature of the heart.

Content

press releases

18 Sep
2024 BioCardia Regains Full Compliance with Nasdaq Listing Requirements
09 Sep
2024 BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
30 Aug
2024 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
29 Aug
2024 BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
21 Aug
2024 FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
13 Aug
2024 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS